Skip to content
  • Contacts
  • facebook
  • twitter
  • linkedin
registration | login

News and Events

The official online journal of the International Conference
on Thrombosis and Hemostasis Issues in Cancer
NEW WEBINAR: Hidden Threats: Understanding Thrombosis in Unusual Sites by ICTHIC Editorial Office 19 December 2024
PROGRAM AVAILABLE: 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) by ICTHIC Editorial Office 24 April 2024
PROGRAM NOW AVAILABLE: 12th International Conference on Thrombosis and Hemostasis Issue in Cancer by ICTHIC Editorial Office 16 April 2024
RECORDINGS ONLINE: Management of CAT in the colorectal cancer patient by ICTHIC Editorial Office 20 February 2024
  • Home
  • Thrombosis and cancer
    • Epidemiology
    • Basic Mechanisms
    • Prevention
    • Trials and Therapy
    • Focus on: Atrial fibrillation
    • Focus on: Pediatrics
    • Focus on: COVID-19
  • Guidelines and Tools
  • Congress reports
    • ICTHIC 2022
    • ICTHIC 2021
    • ISTH 2020
    • ASH 2020
    • ASH 2019
    • ISTH 2019
    • ICTHIC 2018
    • ESC 2018
  • News and Events
  • Past webinars
  • About
  • Contacts
  • Editorial Board
  • Most Read
  • Podcast and videos
  • Archive
  • PARTNERSHIP
Webinar

Home › Anticoagulation Drugs

Anticoagulation Drugs

Heparin-Induced Thrombocytopenia: The Expanding Role of Factor Xa Inhibitors in Therapy

Heparin products, such as unfractionated heparin and low-molecular-weight heparin (LMWH), are commonly employed as...
Author ICTHIC Editorial OfficePosted on 30 August 2024

Navigating Anticoagulation Challenges in Brain Cancer Patients with Venous Thromboembolism: Insights from a Comprehensive Study

Venous thromboembolism (VTE) is a well-established complication in cancer patients, with a 4- to 7-fold higher risk...
Author ICTHIC Editorial OfficePosted on 25 November 202312 December 2023

Navigating Anticoagulation Strategies and Outcomes in Patients with Cancer-Associated Thrombosis and Thrombocytopenia

Thrombocytopenia, a low platelet count (<100 × 109/L), is a common side effect of cancer and its treatment. Its...
Author ICTHIC Editorial OfficeAuthor Tzu-Fei WangAuthor Aurélien DellucAuthor Miriam KimptonPosted on 22 September 202325 September 2023

Insights into CAT: A Cohort Study in US Veterans with Solid and Hematologic Neoplasm

Venous thromboembolism (VTE) is a significant concern for patients with active cancer undergoing systemic therapy, with...
Author ICTHIC Editorial OfficeAuthor Kylee L. MartensAuthor Nathanael FillmorePosted on 22 July 202329 August 2023

The Impact of DDI on the Cancer Patient

Cancer patients are often prescribed more than one drug and the need to elucidate potential harmful interactions...
Author ICTHIC Editorial OfficePosted on 22 December 202222 December 2022

Management of VTE beyond 12 months in patients with cancer-associated thrombosis

During the ICTHIC webinar, “Long-term treatment & DDI implications in the management of CAT,” Dr. Luis...
Author ICTHIC Editorial OfficePosted on 7 November 202219 January 2023

The impact of warfarin on overall survival in cancer patients with VTE

During the 11th ICTHIC, 2022, Jeffrey Zwicker talked about the impact of warfarin on overall survival (OS) in cancer...
Author ICTHIC Editorial OfficePosted on 26 July 202225 July 2022

Low-dose apixaban as secondary prophylaxis in patients with cancer: is it safe?

Recurrent venous thromboembolism (VTE) and major bleeding are the two major challenges in managing cancer-associated...
Author ICTHIC Editorial OfficePosted on 20 February 202221 February 2022

Does warfarin increase overall survival compared to LMWH in CAT treatment?

The treatment of cancer-associated thrombosis (CAT) has changed over the last 20 years, going from warfarin up to the...
Author ICTHIC Editorial OfficePosted on 13 December 202113 January 2022

Use of direct oral anticoagulants in patients with atrial fibrillation and concomitant active cancer

Atrial fibrillation (AF) is common in patients with cancer, and up to one in every four persons with AF has comorbid...
Author ICTHIC Editorial OfficePosted on 8 July 202125 January 2023

Posts pagination

Page 1 Page 2 Next page

ICTHIC magazine is supported by an unrestricted educational grant from

SUBSCRIBE TO OUR NEWSLETTER

I agree to receive updates concerning the content published in ICTHIC MAGAZINE and related promotional content/activities (more details)

ICTHIC magazine is supported by an unrestricted educational grant from

logo polistudium
Scientific and Web contents by Polistudium s.r.l.
via Solferino, 7 - 20121 Milan, Italy
info@polistudium.it
None of the information published on the ICTHIC magazine website, in particular, information related to the choice and use of drugs, replaces the advice of a doctor
© COPYRIGHT 2019 ICTHIC Magazine
Privacy policy
None of the information published on the ICTHC magazine website, in particular, information related to the choice and use of drugs, replaces the advice of a doctor.

Accept to continue
By registering to the newsletter, the User’s email address will be added to the contact list of ICTHIC Magazine, in order to receive email messages concerning the content published in ICTHIC Magazine and related promotional content/activities. Your email address may also be added to this list as a result of signing up to this Website. Personal Data collected: email address, first name, last name, profession.
ICTHIC CONFERENCE Newsletter By registering to the newsletter, the User’s email address will be added to the contact list of ICTHIC, in order to receive newsletters concerning the conference, such as Save the date, information about the meeting venue, the publication of the program, registration fees and deadline, abstract submission deadline and oral communication/poster instructions, hotel booking availability and deadline, social program for accompanying persons, the publication of speakers slides, photo/videogallery of the last edition and information about future editions of the conference. Your email address may also be added to this list as a result of signing up to this Website.